查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470444

胰岛素市场：按药物、类型和应用分类 - 2024-2030 年全球预测

Insulin Market by Drug (Biologic, Biosimilar), Type (Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年胰岛素市场规模为436.4亿美元，预计2024年将达467.6亿美元，2030年将达到730.3亿美元，复合年增长率为7.63%。

胰岛素市场包括用于治疗糖尿病的各种胰岛素类型的生产、分销和消费，糖尿病是一种影响全球数百万人的慢性代谢疾病。胰岛素的主要用途是控制缺乏天然胰岛素产生的 1 型糖尿病患者和胰岛素释放不足或不足的 2 型糖尿病患者的血糖值。该市场包括人类胰岛素、速效和长效胰岛素等现代胰岛素以及生物相似药胰岛素。由于人口老化、医疗保健服务的改善、糖尿病管理意识的提高以及政府支持的扩大胰岛素使用和生产的倡议，糖尿病盛行率不断上升。另一方面，胰岛素的高价格和复杂的法规环境阻碍了市场的成长。然而，随着新型胰岛素的开发和核准率的提高，生物技术的进步预计将在未来几年推动市场成长。

主要市场统计
基准年[2023] 436.4亿美元
预测年份 [2024] 467.6亿美元
预测年份 [2030] 730.3亿美元
复合年增长率（%） 7.63%

由于其安全性、有效性和创新特性，生物製药预计将广泛应用。

生物製药（胰岛素）是天然存在的胰岛素，是利用重组 DNA 技术在细菌或酵母细胞等活体生物体中合成的。这些胰岛素的化学性质与人类胰岛素相同，并且非常模仿人体的正常胰岛素反应。此外，生物胰岛素由于其精确的分子结构和功能，在控制血糖值方面非常有效。生物仿製胰岛素与先前核准的生物製药胰岛素相似，在安全性、纯度或效力方面与参考製剂没有临床上的重要差异。由于与生物相似药製造过程相关的研发成本降低，这些胰岛素通常比其原厂产品便宜。生物相似药胰岛素是首选，因为与原厂生物製药胰岛素相比，它们具有成本效益。生物仿製胰岛素具有相当的功效和安全性，使医疗保健系统能够节省资金，同时又不影响患者的治疗效果。生物製药和生物类似胰岛素之间的选择取决于患者的反应、过敏反应的可能性、医疗保健系统的承受能力和可用性。这两个领域的持续进步预计将透过提供更安全、更有效的治疗方案，同时解决世界各地医疗保健系统面临的成本挑战，进一步改善糖尿病照护。

长效型胰岛素涵盖了较长时间的基础作用。

中效胰岛素旨在长期稳定释放胰岛素。需要更稳定、更持久的胰岛素作用的糖尿病患者可能更喜欢中效胰岛素。长效胰岛素可提供长达 24 小时或更长时间的血糖控制，通常每天给药一次，并且通常与其他形式的胰岛素结合以实现最佳的血糖管理。预混合料胰岛素结合了中效和短效或速效胰岛素，可提供即时和长效血糖控制。速效胰岛素给药后立即起效，控制餐前血糖，非常适合想要快速改善高血糖的患者。短效胰岛素，通常称为常规胰岛素，可在给药后一小时内控制血糖。适合需要立即起效但作用时间比中效胰岛素短的患者。

用途如果I型糖尿病患者大量使用胰岛素，则必须持续监测并及时给药。

I 型糖尿病，也称为胰岛素依赖型糖尿病或幼年型糖尿病，是一种胰臟无法产生足够胰岛素的慢性疾病。因此，I 型糖尿病患者需要外源性胰岛素来调节血糖值。该群体需要具有快速吸收和峰值作用时间的速效胰岛素，以模拟进餐期间的生理胰岛素释放。 II 型糖尿病是最常见的糖尿病类型，其特征是对胰岛素作用的抗性或这种荷尔蒙的产生不足。患有第 2 型糖尿病的人需要多种治疗，从口服药物到非胰岛素注射或胰岛素注射，这取决于疾病的进展。对于这一组，依需求选择24小时内效果稳定的长效基础胰岛素，必要时加用Bolus控制进餐血糖。两种类型的糖尿病都需要有效的血糖控制策略，但根据个人需求考虑特定的胰岛素和辅助性治疗偏好时会出现差异。

区域洞察

在美洲地区，由于主要参与者的存在、更好的医疗基础设施以及疾病管理意识的提高，北美在胰岛素市场上占据主导地位。政府对糖尿病早期诊断和治疗的倡议等因素也对这一增长做出了重大贡献。随着南美洲人口迅速老化，糖尿病患者数量不断增加。墨西哥、巴西等国推出了重点防治糖尿病等非传染性疾病的国家政策，进一步加速了该地区市场的扩张。由于医疗基础设施和产品供应的改善，亚太地区正迅速成为胰岛素的主要市场。此外，亚太地区国家正在大力投资研发，以生产具有成本效益的胰岛素产品。近年来，该地区对胰岛素笔和胰岛素帮浦等先进胰岛素输送系统的采用激增。随着越来越多的人意识到糖尿病管理选择，预计亚太地区国家对胰岛素和相关设备的需求将会增加。由于医疗基础设施的改善和创新胰岛素治疗方法的改善，西欧的胰岛素市场正在快速成长。在中东和非洲地区，医疗基础设施的改善以及政府和国际组织的措施正在支持胰岛素市场的成长。南非等国家已出台政策，透过健康促进策略来对抗包括糖尿病在内的非传染性疾病，这可能会推动该领域的市场成长。

FPNV定位矩阵

FPNV定位矩阵对于评估胰岛素市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对胰岛素市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 胰岛素市场规模及预测如何？

2.胰岛素市场预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3. 胰岛素市场的技术趋势和法规结构是什么？

4.胰岛素市场主要厂商的市场占有率是多少？

5. 进入胰岛素市场的合适型态或策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着人口老化的加剧，糖尿病和肥胖症的发生率上升
      • 胰岛素输送系统的快速发展
      • 已开发国家胰岛素产品优惠报销政策
    • 抑制因素
      • 与胰岛素药物相关的高成本
    • 机会
      • 胰岛素研发活动的潜在投资
      • 增加对兼容生物相似药胰岛素产品的核准
    • 任务
      • 复杂的监管环境以及患者遵守治疗计划的问题
  • 市场区隔分析
    • 药品：安全、有效、创新的生物药品的重要用途
    • 类型：长效胰岛素在较长时间内覆盖基础胰岛素。
    • 应用：第1型糖尿病患者大量使用胰岛素，需持续监测并及时给予胰岛素。
  • 市场趋势分析
    • 成熟的医疗基础设施和实惠产品的开发正在支持整个美洲的市场成长。
    • 政府支持提高亚太地区胰岛素的可及性和利用率
    • 欧洲、中东和非洲地区的胰岛素研发活动和报销政策的可用性
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章按药物分類的胰岛素市场

  • 生物
  • 生物相似药

第七章胰岛素市场：依类型

  • 中效胰岛素
  • 长效胰岛素
  • 预混合料胰岛素
  • 速效胰岛素
  • 短效胰岛素

第八章胰岛素市场：依应用分类

  • 1型糖尿病
  • 2型糖尿病

第九章美洲胰岛素市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太胰岛素市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲胰岛素市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 胰岛素製造商Genesis投资500-6000万美元在海得拉巴建工厂
    • 海湾製药工业「Julfar」与 Sunshine Lake Pharma 签署突破性协议，成为中东和北非地区生物相似药製造的先驱
    • 赛诺菲在印度推出新的长效药物
    • 加州和製药公司合作生产负担得起的胰岛素
    • 诺和诺德为印度患者推出每週胰岛素治疗
    • ADOCIA宣布与合作伙伴通化东宝合作生物伴侣赖ChaperoneLispro一期试验取得成功
    • Glenmark在印度推出第二型糖尿病及高抗药性药物，股价大涨
    • 礼来公司和 EVA Pharma 宣布建立合作伙伴关係，以加强非洲可持续获得负担得起的胰岛素
    • 诺和诺德推出 Tresiba 类似物生物製药胰岛素，以扩大患者的购买选择
    • Optum 和赛诺菲合作为未投保者提供低成本胰岛素

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-03548A2B9FF7

[199 Pages Report] The Insulin Market size was estimated at USD 43.64 billion in 2023 and expected to reach USD 46.76 billion in 2024, at a CAGR 7.63% to reach USD 73.03 billion by 2030.

The insulin market encompasses the production, distribution, and consumption of various insulin types used to treat diabetes mellitus, a chronic metabolic disorder affecting millions worldwide. The primary application of insulin is to control blood sugar levels in patients with type 1 diabetes who lack natural insulin production and those with type 2 diabetes who have developed insufficient or insufficient insulin release. The scope of this market includes human insulin, modern insulins such as rapid-acting and long-acting, and biosimilar insulins. Increasing prevalence of diabetes due to aging populations, improved access to healthcare services, increased awareness about diabetes management, and supportive government initiatives to expand the use and production of insulin. On the other hand, the high cost of insulin and the complex regulatory environment hinder the market growth. However, advancements in biotechnology, which have led to development of novel insulins and increasing approval rates, are expected to proliferate the market growth in the coming years.

KEY MARKET STATISTICS
Base Year [2023] USD 43.64 billion
Estimated Year [2024] USD 46.76 billion
Forecast Year [2030] USD 73.03 billion
CAGR (%) 7.63%

Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features

Biologic insulin is naturally occurring insulin synthesized using recombinant DNA technology in living organisms, such as bacteria or yeast cells. These insulins are chemically identical to human insulin and closely mimic the body's normal insulin response. Additionally, biological insulins demonstrate high efficacy in controlling blood sugar levels due to their precise molecular structure and function. Biosimilar insulins are similar to biologic insulins that have previously received approval and have no clinically significant variations from their reference products regarding safety, purity, or potency. These insulins are often more affordable than their branded counterparts due to reduced research and development costs associated with the biosimilars' production process. Preference for biosimilar insulin arises from its cost-effectiveness compared to branded biologic insulin options. It provides comparable efficacy and safety profiles, allowing healthcare systems to save on expenses without compromising patient outcomes. The choice between biologic or biosimilar insulin depends on patient response, potential allergic reactions, healthcare system affordability concerns, and accessibility. Continued advancements in both segments are expected to further enhance diabetes care by providing safer and more effective treatment options while addressing the cost challenges healthcare systems worldwide face.

Type: Long-acting insulins provide basal coverage for an extended duration

Intermediate-acting insulin is designed to provide a steady insulin release over an extended period. People with diabetes who require a more stable and longer-lasting insulin effect may prefer intermediate-acting insulin. Long-acting insulin offers prolonged blood sugar control, lasting up to 24 hours or more, usually administered once daily, and is often combined with other forms of insulin for optimal glucose management. Premixed insulin combines intermediate-acting and short- or rapid-acting insulins, offering both immediate and sustained blood sugar control. Rapid-acting insulin works quickly after administration, controlling blood sugar before a meal, which is ideal for patients who need rapid correction of high blood glucose levels. Short-acting insulin, commonly known as regular insulin, controls blood sugar less than an hour after administration. It is suitable for patients who require a fast onset but shorter duration of action than intermediate-acting insulins.

Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin

Type I diabetes, also called insulin-dependent or juvenile diabetes, is a chronic disease described by the incapacity of the pancreas to produce adequate insulin. As a result, patients with Type I diabetes require exogenous insulin to regulate their blood glucose levels. The need-based preference for this group is fast-acting insulins that provide rapid absorption and peak action time to mimic physiological insulin release during meals. Type II diabetes is the most common form of diabetes, characterized by resistance to the effects of insulin or insufficient production of this hormone. Patients with Type II diabetes may require various treatments ranging from oral medications to non-insulin injectable drugs or insulin injections, depending on disease progression. The need-based preference for this group includes long-acting basal insulins providing steady coverage over 24 hours and additional bolus injections if required for mealtime blood sugar control. Although both types of diabetes necessitate effective blood glucose management strategies, distinctions arise when considering the preferences for specific insulins or adjunct therapies based on individual needs.

Regional Insights

In the Americas region, North America dominates the insulin market due to the presence of key players, better healthcare infrastructure, and increased awareness regarding disease management. Factors such as government initiatives for early diagnosis and treatment of diabetes are also contributing significantly to this growth. South America is witnessing rising cases of diabetes amidst its rapidly aging population. Countries such as Mexico and Brazil have introduced national policies focusing on preventing and controlling non-communicable diseases, including diabetes, further accelerating market expansion in the region. The Asia-Pacific region is fast emerging as a major market for insulin due to its improvements in healthcare infrastructure and product availability. Furthermore, APAC countries have invested heavily in research and development to produce cost-effective insulin products. In recent years, there has been a surge in the adoption of advanced insulin delivery systems, such as insulin pens and pumps, in the region. As more people become aware of diabetes management options, the demand for insulin and associated devices is projected to increase across APAC countries. Western Europe's insulin market is growing rapidly due to its well-established healthcare infrastructure and increased accessibility to innovative insulin therapies. In the Middle East and Africa region, improving healthcare infrastructure and efforts made by government and international organizations support insulin market growth. Countries such as South Africa are introducing policies to combat non-communicable diseases, including diabetes, through health promotion strategies, which could drive market growth in this area.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Insulin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Insulin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Insulin Market, highlighting leading vendors and their innovative profiles. These include ADOCIA, AstraZeneca PLC, Baxter International, Inc., Biocon Limited, Bioton S.A., CardioVends, Eli Lilly and Company, Eva Pharma, GeneSys Biologics, Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries (Julphar), MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi Group, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., Wockhardt Limited, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Insulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Biologic
    • Biosimilar
  • Type
    • Intermediate-acting Insulin
    • Long-acting Insulin
    • Premixed Insulin
    • Rapid-acting Insulin
    • Short-acting Insulin
  • Application
    • Type I Diabetes
    • Type II Diabetes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Insulin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Insulin Market?

3. What are the technology trends and regulatory frameworks in the Insulin Market?

4. What is the market share of the leading vendors in the Insulin Market?

5. Which modes and strategic moves are suitable for entering the Insulin Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of diabetes and obesity with increasing geriatric population
      • 5.1.1.2. Rapid development in insulin delivery systems
      • 5.1.1.3. Favorable reimbursement policies for insulin products in developed countries
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with insulin drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Potential investments in R&D activities for insulin development
      • 5.1.3.2. Rising approvals for interchangeable biosimilar insulin products
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscape and problems related to patient adherence to treatment regimens
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features
    • 5.2.2. Type: Long-acting insulins provide basal coverage for an extended duration
    • 5.2.3. Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin
  • 5.3. Market Trend Analysis
    • 5.3.1. Established healthcare infrastructure and development of affordable product have supplemented market growth across the Americas
    • 5.3.2. Government support to increase accessibility and usage of insulin in APAC region
    • 5.3.3. Research & development activities and availability of reimbursement policies for insulin in the EMEA region
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Insulin Market, by Drug

  • 6.1. Introduction
  • 6.2. Biologic
  • 6.3. Biosimilar

7. Insulin Market, by Type

  • 7.1. Introduction
  • 7.2. Intermediate-acting Insulin
  • 7.3. Long-acting Insulin
  • 7.4. Premixed Insulin
  • 7.5. Rapid-acting Insulin
  • 7.6. Short-acting Insulin

8. Insulin Market, by Application

  • 8.1. Introduction
  • 8.2. Type I Diabetes
  • 8.3. Type II Diabetes

9. Americas Insulin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Insulin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Insulin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad
    • 12.3.2. Gulf Pharmaceutical Industries 'Julphar' Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA
    • 12.3.3. Sanofi Launches New Long-Acting Insulin Drug in India
    • 12.3.4. California, Drugmaker Partner to Produce Affordable Insulin
    • 12.3.5. Novo Nordisk to Launch Once-a-Week Insulin Regime for Indian Patients
    • 12.3.6. ADOCIA Announces the Successful Phase 1 Study for BioChaperone Lispro with Partner Tonghua Dongbao
    • 12.3.7. Glenmark Launches Type 2 Diabetes and High Insulin Resistance Drug in India; Shares Jump
    • 12.3.8. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
    • 12.3.9. Novo Nordisk Launches Unbranded Biologic of Tresiba Analog Insulin to Expand Affordability Options for Patients
    • 12.3.10. Optum, Sanofi Partner on Low Cost Insulin for the Uninsured

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. INSULIN MARKET RESEARCH PROCESS
  • FIGURE 2. INSULIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INSULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INSULIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INSULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INSULIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INSULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INSULIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INSULIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INSULIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INSULIN MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INSULIN MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INSULIN MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INSULIN MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INSULIN MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INSULIN MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INSULIN MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INSULIN MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INSULIN MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INSULIN MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023